Search

Your search keyword '"Oldaker, Teri"' showing total 28 results
Start Over Author "Oldaker, Teri"
28 results on '"Oldaker, Teri"'

1. Flow Cytometry Method Validation Protocols

Author

Selliah, Nithianandan, primary, Nash, Veronica, additional, Eck, Steven, additional, Green, Cherie, additional, Oldaker, Teri, additional, Stewart, Jennifer, additional, Vitaliti, Alessandra, additional, and Litwin, Virginia, additional

Published
2023
Full Text
View/download PDF

8. ICCS Women in Cytometry—Impact 10 years later: A call to promote gender equity

Author

Bunting, Silvia T., primary, Oldaker, Teri, additional, Qualtieri, Julianne, additional, O'Donahue, Melanie, additional, Maremont, Sara, additional, Harricharran, Heather, additional, Kelliher, Abigail, additional, Kdouh, Lama, additional, Devitt, Katherine, additional, Cherian, Sindhu, additional, Stetler‐Stevenson, Maryalice, additional, and Moore, Jonni, additional

Published
2020
Full Text
View/download PDF

11. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer

Author

Clark, Gary M., Wenger, Charlotte R., Beardslee, Susan, Owens, Marilyn A., Pounds, George, Oldaker, Teri, Vendely, Patricia, Pandian, M.R., Harrington, Douglas, and McGuire, William L.

Subjects
Breast cancer -- Prognosis, Hormone receptors, Flow cytometry -- Diagnostic use, Health
Abstract

A large group of patients with node-positive breast cancer was divided into a training set (n = 851) and a validation set (n = 432) to demonstrate techniques for integrating steroid hormone receptor status, DNA flow cytometric findings, and other prognostic factors to predict patient survival. Multivariate analyses showed that estrogen receptor status, the number of involved axillary lymph nodes, patient age, S-phase fraction, progesterone receptor status, and tumor size were significant predictors of survival in patients with node-positive breast cancer. Techniques for optimizing and validating a cut point for a new prognostic factor and for examining alternative representations of prognostic factors were demonstrated. Prognostic indexes were created that could be used to identify patients with very good or very poor prognoses. Cancer 1993; 71:2157-62.

Published
1993

14. Flow Cytometry Method Validation Protocols

Author

Selliah, Nithianandan, primary, Eck, Steven, additional, Green, Cherie, additional, Oldaker, Teri, additional, Stewart, Jennifer, additional, Vitaliti, Alessandra, additional, and Litwin, Virginia, additional

Published
2018
Full Text
View/download PDF

20. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry

Author

Clark, Gary M., Dressler, Lynn G., Owens, Marilyn A., Pounds, George, Oldaker, Teri, and McGuire, William L.

Subjects
Breast cancer -- Prognosis, Cancer -- Prognosis, Flow cytometry -- Diagnostic use, DNA -- Analysis
Abstract

In approximately half of the women diagnosed with breast cancer, the disease is restricted to the breast itself, with no evidence of cancer cells found in the neighboring lymph nodes. The availability of early breast cancer detection has made the diagnosis of more node-negative cancers. Even though the prognosis is good, 30 percent of the women with no nodal involvement die from the cancer. Treatment of node-negative breast cancers is controversial, and some practitioners give extra therapy. Factors influencing prognosis may help physicians select those patients who would benefit the most from such potentially toxic additional therapy. Diseased tissue in 395 frozen samples was analyzed for specific cell type and behavior by DNA flow-cytometry. Patients with aneuploid (cells with abnormal amount of chromosomes) tumors had five-year survival rates of 74 percent, compared with 88 percent among patients with diploid tumors (normal number of chromosomes). In the latter case, low S-phase fractions (a specific synthesis phase of a cell cycle) indicated 90 percent survival at five years and high values indicated a survival of 70 percent. This method of evaluating the characteristics of tumor cells is a meaningful indicator of survival of node-negative breast cancer patients. Patients with diploid, low S-phase tumors have good prognosis and may not be good candidates for adjuvant therapy.

Published
1989

24. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia

Author

Wood, Brent L., primary, Arroz, Maria, additional, Barnett, David, additional, DiGiuseppe, Joseph, additional, Greig, Bruce, additional, Kussick, Steven J., additional, Oldaker, Teri, additional, Shenkin, Mark, additional, Stone, Elizabeth, additional, and Wallace, Paul, additional

Published
2007
Full Text
View/download PDF

28. Flow Cytometry Method Validation Protocols

Author

Selliah, Nithianandan, Eck, Steven, Green, Cherie, Oldaker, Teri, Stewart, Jennifer, Vitaliti, Alessandra, and Litwin, Virginia

Abstract

Analytical method validation provides a means to ensure that data are credible and reproducible. This unit will provide a brief introduction to analytical method validation as applied to cellular analysis by flow cytometry. In addition, the unit will provide practical procedures for three different types of validation. The first is a limited validation protocol that is applicable for research settings and non‐regulated laboratories. The second is validation protocol that presents the minimum validation requirements in regulated laboratories. The third is a transfer validation protocol to be used when methods are transferred between laboratories. The recommendations presented in this unit are consistent with the white papers published by the American Association of Pharmaceutical Scientists and the International Clinical Cytometry Society, as well as with Clinical Laboratory Standards Institute Guideline H62: Validation of Assays Performed by Flow Cytometry (currently in preparation). © 2018 by John Wiley & Sons, Inc.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results